NewAmsterdam Pharma Wins EU Approval for Cholesterol Medications
NewAmsterdam Pharma (NASDAQ:NAMS) has received European Commission approval for two cholesterol-lowering drugs: Ubeslo, containing obicetrapib, and Evlarco, a combination of obicetrapib with ezetimibe. These are the first global approvals for these products, targeting adults with high cholesterol or mixed lipid disorders who may need additional LDL-C reduction beyond existing therapies. The company will earn tiered royalties from net sales in Europe through its licensing agreement with Menarini Group, which holds exclusive commercialization rights. The approval cites significant reductions in bad cholesterol levels compared to placebo across Phase 3 trials. However, the long-term success of these drugs depends on factors such as patient adoption, pricing negotiations, and reimbursement decisions. NewAmsterdam also stands to gain up to €833 million from milestone payments tied to clinical or commercial achievements. Despite a strong cash position of $678.3 million as of June 2026, the company remains in development mode with ongoing R&D costs.
Tickers: $NAMS
Topics: cholesterol drugs eu approvals pharmaceuticals royalties